Ikris Pharma
About Us Named Patient Program
Cities We Serve Contact Us

Leukemia

Leukemia Medicines in India: Imported Options for AML, ALL, CLL and CML

Written by Nitin Goswami Medically reviewed by Dr. Chirag C Shah Last updated
QUICK ANSWERLeukemia is a cancer of the blood-forming cells in the bone marrow. It is not one illness: doctors split it into acute myeloid (AML), acute lymphoblastic (ALL), chronic lymphocytic (CLL) and chronic myeloid (CML) leukemia, and each type has its own medicines. India recorded an estimated 49,542 new leukemia cases and 32,731 leukemia deaths in 2024 [1], and leukemia is the most frequent cancer in Indian children [3]. Many newer leukemia medicines work only when a bone marrow test finds a particular gene change, such as FLT3, NPM1, IDH2 or the Philadelphia chromosome. Named Patient Program (NPP) can import all 16 medicines listed here for one named patient, against a prescription from the treating hematologist or oncologist.
49,542
people in India were newly diagnosed with leukemia in 2024, making it the 8th most common cancer in the country (3.2% of all new cases)
Source: IARC GLOBOCAN 2024 [1]
10.0%
of the world's new leukemia cases in 2024 were in India: 49,542 of 495,113
Source: GLOBOCAN 2024, IARC [1, 2]
40%
of cancers in Indian children aged 0 to 14 were leukemias, in hospital registry records of 2012 to 2019
Source: ICMR-NCDIR hospital registries [3]
27.9%
of 165 newly diagnosed AML patients in Assam carried an NPM1 mutation, and 14.6% a FLT3-ITD change
Source: Indian J Hematol Blood Transfus, 2018 [4]

The four main types of leukemia and how they differ

"Acute" leukemia grows over days to weeks and needs treatment straight away. "Chronic" leukemia usually moves more slowly and may be found on a routine blood count. "Myeloid" and "lymphocytic" (or lymphoblastic) tell you which family of blood cells has turned cancerous. Put together, that gives four main types:

TypeCells involvedWhat Indian data showMedicines on this page
AML – acute myeloid leukemiaImmature myeloid cells (the line that makes granulocytes, red cells and platelets)In 165 new AML patients in Assam, NPM1 was the commonest gene change found (46 people) [4]Cytosar, Vyxeos, Mylotarg, Vanflyta, Xospata, Idhifa, Komzifti, Revuforj, Inqovi
ALL – acute lymphoblastic leukemiaImmature B or T lymphocytesThe leading childhood cancer group in Indian hospital registries [3]Blincyto, Iclusig, Atriance, Erwinase, Revuforj, Cytosar
CLL – chronic lymphocytic leukemiaMature-looking B lymphocytesLess common in India than in the West, and often seen at a younger age [10]Jaypirca, Lisaftoclax, Sonrotoclax
CML – chronic myeloid leukemiaMyeloid cells carrying the BCR-ABL1 (Philadelphia) changeCalled the commonest adult leukemia in India by a Kolkata team; median age 36 in their series [8]Iclusig, Cytosar

Leukemia in India: the 2024 numbers

IARC's GLOBOCAN 2024 estimates give India 49,542 new leukemia cases and 32,731 deaths in that year. Leukemia ranked 8th among new cancers and 9th among cancer deaths, with 131,383 people living within five years of a leukemia diagnosis [1].

Worldwide the same source counts 495,113 new cases, of which Asia accounts for 48.0% [2]. India's share works out to 49,542 ÷ 495,113 = 10.0%.

The picture in children is different from adults. Out of 60,720 cancers in people aged 0 to 19, recorded by 96 hospital-based registries between 2012 and 2019, leukemia made up 40% of cases in the 0 to 14 group and 36% in the 0 to 19 group [3].

What Indian treatment studies report

  • Childhood ALL can do well with full treatment. At Goa Medical College, 50 patients below 25 years (median age 6) were treated on a modified BFM-2009 protocol. 94% were in complete remission after induction, and at 3 years event-free survival was 75.2% and overall survival 78.3% [5].
  • ALL in adults over 40 is much harder. In a multicentre Hematology Cancer Consortium registry, 135 of 349 patients aged 40 and above (38.6%) did not start treatment. Among the 214 who did, 18.6% died during induction, mostly of infection, and 3-year overall survival was 31% [6].
  • Childhood AML carries a high treatment risk. At a Tata Memorial Centre hospital in Varanasi, treatment-related mortality among 59 children with AML reached 30%. Of the 43 who received intensive chemotherapy, 27.9% were alive at 3 years [7].
  • Gene results shape AML outlook. In the Assam series, NPM1-mutated AML had a higher complete remission rate and longer survival, while FLT3-ITD was linked to poorer survival [4].
  • CML has changed with tablets. In 76 newly diagnosed chronic-phase patients in Kolkata treated with generic imatinib, 97% reached a complete blood count response, and 44% had a major molecular response at 12 months [8]. An earlier national data meeting on 8,115 Indian CML patients confirmed a younger age at presentation and poorer results when treatment began in late chronic phase [9].

Which test result points to which medicine

For most of the imported options below, the approval is tied to a laboratory finding. The table links the common results to the medicines on this page; your hematologist decides whether any of them applies to you.

Test resultLeukemia typeMedicines on this page
FLT3-ITD at diagnosisNewly diagnosed AMLVanflyta (with standard chemotherapy, then as maintenance)
FLT3 mutation at relapseRelapsed or refractory AMLXospata
IDH2 mutationRelapsed or refractory AMLIdhifa
NPM1 mutationRelapsed or refractory AMLKomzifti, Revuforj
KMT2A translocationRelapsed or refractory acute leukemiaRevuforj
CD33 on the leukemia cellsAML, new or relapsedMylotarg
CD19 on B-cell blasts, or MRD of 0.1% or moreB-cell precursor ALLBlincyto
Philadelphia chromosome / T315IPh+ ALL and CMLIclusig
Earlier BTK inhibitor treatmentCLL / SLLJaypirca, Lisaftoclax, Sonrotoclax

Imported leukemia medicines by type

All 16 medicines below are prescription-only. Tap a type to filter. Each card opens the full medicine page with dosage, storage and safety details.

Cytosar (cytarabine)
Cytosar
cytarabine · Injection
With other anticancer medicines to bring acute myeloid (non-lymphocytic) leukemia into remission; also used in ALL, blast-phase CML and, by intrathecal injection, meningeal leukemia
Acute myeloid (AML)Acute lymphoblastic (ALL)Chronic myeloid (CML) US FDA
Vyxeos (daunorubicin + cytarabine (liposomal))
Vyxeos
daunorubicin + cytarabine (liposomal) · IV infusion
Newly diagnosed AML that followed earlier cancer treatment (t-AML), or AML showing myelodysplasia-related changes; adults and children from 1 year
Acute myeloid (AML) US FDA
Mylotarg (gemtuzumab ozogamicin)
Mylotarg
gemtuzumab ozogamicin · IV infusion
CD33-positive AML: newly diagnosed (from 1 month of age) or relapsed/refractory (from 2 years of age)
Acute myeloid (AML) US FDA
Vanflyta (quizartinib)
Vanflyta
quizartinib · Tablet
Adults with newly diagnosed FLT3-ITD-positive AML, with standard induction and consolidation chemotherapy and then alone as maintenance (not after a stem cell transplant)
Acute myeloid (AML) US FDA
Xospata (gilteritinib)
Xospata
gilteritinib · Tablet
Adults whose AML has relapsed or not responded and carries a FLT3 mutation
Acute myeloid (AML) US FDA
Idhifa (enasidenib)
Idhifa
enasidenib · Tablet
Adults with relapsed or refractory AML carrying an IDH2 mutation
Acute myeloid (AML) US FDA
Komzifti (ziftomenib)
Komzifti
ziftomenib · Capsule
Adults with relapsed or refractory AML that has a susceptible NPM1 mutation, when no satisfactory alternative treatment exists
Acute myeloid (AML) US FDA
Revuforj (revumenib)
Revuforj
revumenib · Tablet
Relapsed or refractory acute leukemia with a KMT2A translocation, or relapsed/refractory AML with a susceptible NPM1 mutation and no satisfactory alternative; age 1 year and older
Acute myeloid (AML)Acute lymphoblastic (ALL) US FDA
Inqovi (decitabine + cedazuridine)
Inqovi
decitabine + cedazuridine · Tablet
With venetoclax for newly diagnosed AML in adults aged 75 or more, or unfit for intensive induction; also approved for MDS, including chronic myelomonocytic leukemia (CMML)
Acute myeloid (AML) US FDA
Blincyto (blinatumomab)
Blincyto
blinatumomab · IV infusion
CD19-positive B-cell precursor ALL from 1 month of age: in remission with MRD of 0.1% or more, relapsed or refractory, or Ph-negative disease in consolidation
Acute lymphoblastic (ALL) US FDA
Iclusig (ponatinib)
Iclusig
ponatinib · Tablet
Adults with Ph-positive ALL (new, with chemotherapy; or alone when no other kinase inhibitor fits, or with T315I) and CML after two kinase inhibitors, in advanced phase or with T315I
Acute lymphoblastic (ALL)Chronic myeloid (CML) US FDA
Atriance (nelarabine)
Atriance
nelarabine · IV infusion
T-cell ALL or T-cell lymphoblastic lymphoma that has not responded to, or has relapsed after, at least two chemotherapy regimens; age 1 year and older
Acute lymphoblastic (ALL) US FDA (as Arranon)
Erwinase (asparaginase Erwinia chrysanthemi)
Erwinase
asparaginase Erwinia chrysanthemi · Injection
Part of multi-agent chemotherapy for ALL in patients who have developed an allergy (hypersensitivity) to E. coli-derived asparaginase
Acute lymphoblastic (ALL) UK / Europe
Jaypirca (pirtobrutinib)
Jaypirca
pirtobrutinib · Tablet
Adults with CLL/SLL: previously untreated with no known 17p deletion, or relapsed/refractory after a covalent BTK inhibitor (also approved for mantle cell lymphoma)
Chronic lymphocytic (CLL) US FDA
Lisaftoclax (lisaftoclax)
Lisaftoclax
lisaftoclax · Tablet
BCL-2 inhibitor for adult CLL/SLL that was treated before, where the earlier therapy included a BTK inhibitor (conditional approval, July 2025)
Chronic lymphocytic (CLL) China NMPA
Sonrotoclax (sonrotoclax)
Sonrotoclax
sonrotoclax · Tablet
BCL-2 inhibitor for adults with CLL/SLL treated before with a BTK inhibitor (China conditional approval, December 2025); its US approval covers mantle cell lymphoma only
Chronic lymphocytic (CLL) China NMPA

Compare all 16 leukemia medicines

MedicineGeneric nameLeukemia typeFormApproved by
CytosarcytarabineAcute myeloid (AML), Acute lymphoblastic (ALL), Chronic myeloid (CML)InjectionUS FDA
Vyxeosdaunorubicin + cytarabine (liposomal)Acute myeloid (AML)IV infusionUS FDA
Mylotarggemtuzumab ozogamicinAcute myeloid (AML)IV infusionUS FDA
VanflytaquizartinibAcute myeloid (AML)TabletUS FDA
XospatagilteritinibAcute myeloid (AML)TabletUS FDA
IdhifaenasidenibAcute myeloid (AML)TabletUS FDA
KomziftiziftomenibAcute myeloid (AML)CapsuleUS FDA
RevuforjrevumenibAcute myeloid (AML), Acute lymphoblastic (ALL)TabletUS FDA
Inqovidecitabine + cedazuridineAcute myeloid (AML)TabletUS FDA
BlincytoblinatumomabAcute lymphoblastic (ALL)IV infusionUS FDA
IclusigponatinibAcute lymphoblastic (ALL), Chronic myeloid (CML)TabletUS FDA
AtriancenelarabineAcute lymphoblastic (ALL)IV infusionUS FDA (as Arranon)
Erwinaseasparaginase Erwinia chrysanthemiAcute lymphoblastic (ALL)InjectionUK / Europe
JaypircapirtobrutinibChronic lymphocytic (CLL)TabletUS FDA
LisaftoclaxlisaftoclaxChronic lymphocytic (CLL)TabletChina NMPA
SonrotoclaxsonrotoclaxChronic lymphocytic (CLL)TabletChina NMPA

Reports to keep ready before the prescription

ReportWhy the doctor needs it
Bone marrow aspirate and biopsyConfirms the leukemia type and the share of blast cells
Flow cytometry (immunophenotyping)Separates B-cell from T-cell ALL and shows markers such as CD19 or CD33
Cytogenetics and molecular panelLooks for FLT3, NPM1, IDH2, KMT2A and BCR-ABL1 changes; without these results the gene-based medicines cannot be chosen
MRD reportMeasurable residual disease after treatment; Blincyto is approved for B-cell ALL in remission with MRD of 0.1% or more
Treatment historyLists earlier chemotherapy cycles, kinase inhibitors or BTK inhibitors, since several approvals apply only after these

In the AIIMS New Delhi review of CLL care, the authors note that access to molecular profiling is still limited in many parts of India and that this directly affects treatment choice [10]. Ask your centre early where the gene panel will be sent and how long it takes.

Import permit, hospital delivery and cost help

Every consignment is for a single named patient. The patient's application to CDSCO is made on Form 12A, which our pharmacist prepares, and CDSCO then issues the Form 12B permit covering that import. Our Form 12A and 12B guide lists the documents involved.

Blincyto, Mylotarg, Vyxeos, Cytosar, Atriance and Erwinase are given in hospital, so the shipment can be sent straight to the hospital pharmacy. How the cold chain is kept on the way is described on the hospital delivery in India page. Most of the targeted tablets and capsules on this page are taken at home.

Leukemia treatment often runs in several phases over months or years. Company access schemes and charitable help that some families use are gathered in the support and access programs section of our site.

How to get these leukemia medicines in India

1

Prescription
Your doctor prescribes the medicine.

2

Share documents
Send the prescription and latest reports through Online Order.

3

Import paperwork
Our team checks the source and the import permissions.

4

Delivery
Delivered with the right storage, including cold chain.

Read How to Order and Indian import regulations. We also serve patients in Delhi NCR, Bangalore, Chennai, Mumbai, Kolkata, Hyderabad and Pune.

Has your doctor prescribed one of these medicines?

Share the prescription and we will guide you on availability and next steps.

Online Order

Read more about leukemia

References

  1. IARC Global Cancer Observatory. GLOBOCAN 2024 – India fact sheet (September 2026). https://gco.iarc.who.int/media/globocan/factsheets/populations/356-india-fact-sheet.pdf
  2. IARC Global Cancer Observatory. GLOBOCAN 2024 – Leukaemia fact sheet (July 2026). https://gco.iarc.who.int/media/globocan/factsheets/cancers/36-leukaemia-fact-sheet.pdf
  3. Kapoor G et al. Profile of childhood cancers from hospital-based cancer registries in India, 2012-19. Indian Pediatr. 2024;61(1):39-44. https://pubmed.ncbi.nlm.nih.gov/38183250/
  4. Bhattacharyya J et al. Prevalence and clinical significance of FLT3 and NPM1 mutations in acute myeloid leukaemia patients of Assam, India. Indian J Hematol Blood Transfus. 2018;34(1):32-42. https://pubmed.ncbi.nlm.nih.gov/29398797/
  5. Borker AS, Kanani DJ. Outcomes of acute lymphoblastic leukemia in children and young adults treated with a Berlin-Frankfurt-Münster-based protocol in a tertiary care multispecialty government hospital. Indian J Cancer. 2026;63(2):153-159. https://pubmed.ncbi.nlm.nih.gov/42714196/
  6. Jain P et al. Outcomes of adults age 40 years and older with newly diagnosed ALL: a multicenter registry analysis from the Hematology Cancer Consortium. JCO Glob Oncol. 2026;12(7):e2600090. https://pubmed.ncbi.nlm.nih.gov/42525909/
  7. Srinivasan S et al. Cost-effectiveness of treating childhood acute myeloid leukemia at a tertiary care center in North India. Pediatr Blood Cancer. 2024;71(11):e31242. https://pubmed.ncbi.nlm.nih.gov/39126354/
  8. Phukan A et al. Efficacy and safety profile of generic imatinib in patients with newly diagnosed chronic myeloid leukemia-chronic phase: experience from eastern India. Ann Hematol. 2021;100(1):85-96. https://pubmed.ncbi.nlm.nih.gov/33025163/
  9. Bansal S et al. Chronic myeloid leukemia data from India. Indian J Med Paediatr Oncol. 2013;34(3):154-158. https://pubmed.ncbi.nlm.nih.gov/24516297/
  10. Sahni S et al. Chronic lymphocytic leukemia management in India: balancing evidence, access, and affordability in clinical practice. Front Oncol. 2026;16:1853089. https://pubmed.ncbi.nlm.nih.gov/42528663/
  11. US FDA prescribing information for each US-approved medicine (DailyMed). https://dailymed.nlm.nih.gov/dailymed/

This page gives general information only and does not replace medical advice. All medicines listed are prescription-only and must be used under a qualified doctor.

Leukemia Medicines:
Questions Patients Ask

Short answers to what patients and families ask us most.

More FAQs

Meet the NPP Assistant: ask us anything about NPP